Literature DB >> 23747600

Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation.

Abhishek Singla1, William J Hogan, Stephen M Ansell, Francis K Buadi, David Dingli, Angela Dispenzieri, Dennis A Gastineau, Morie A Gertz, Suzanne R Hayman, David J Inwards, Patrick B Johnston, Martha Q Lacy, Mark R Litzow, Ivana N Micallef, Luis F Porrata, Shaji K Kumar.   

Abstract

Arrhythmias, especially supraventricular arrhythmias, often complicate the clinical course during autologous hematopoietic cell transplantation (AHCT). We wanted to determine the incidence and risk factors for cardiac arrhythmias during AHCT. The study included 983 patients (median age, 58 years [range, 19 to 77]; 61% male) who underwent AHCT between August 2006 and December 2010 at a single institution and for whom all relevant medical records were available for review. AHCT was done for plasma cell disorders in 58% patients and for lymphoma or leukemia in the remaining. Overall, 92 patients (9.4%) developed a supraventricular tachyarrhythmia at a median of 9 days posttransplantation (range, 0 to 18) and with a median duration of less than 1 day (range, <1 to 17 days). Atrial fibrillation was the most common and seen in 71 patients (7%), followed by atrial flutter and supraventricular tachycardia in 12 (1%) and 8 (1%) patients, respectively. In multivariate analysis, age older than 63 years, presence of premature supraventricular complexes or atrioventricular conduction delay on pretransplantation electrocardiogram, and history of any prior arrhythmia increased the risk of arrhythmia. Development of arrhythmia resulted in longer outpatient follow-up after AHCT, with the median follow-up for those developing an arrhythmia of 22 days compared with 19 days for the rest; P < .001. In conclusion, 9% of patients undergoing ASCT developed supraventricular arrhythmias posttransplantation, and this risk was elevated among older patients, those with a prior history of arrhythmias, and those with pretransplantation electrocardiographic abnormalities.
Copyright © 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antiarrhythmics; Arrhythmia; Atrial fibrillation; Autologous hematopoietic cell transplant (AHCT); Electrocardiogram (ECG)

Mesh:

Year:  2013        PMID: 23747600      PMCID: PMC3752294          DOI: 10.1016/j.bbmt.2013.05.019

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  26 in total

1.  Hematopoietic stem cell transplantation: a global perspective.

Authors:  Alois Gratwohl; Helen Baldomero; Mahmoud Aljurf; Marcelo C Pasquini; Luis Fernando Bouzas; Ayami Yoshimi; Jeff Szer; Jeff Lipton; Alvin Schwendener; Michael Gratwohl; Karl Frauendorfer; Dietger Niederwieser; Mary Horowitz; Yoshihisa Kodera
Journal:  JAMA       Date:  2010-04-28       Impact factor: 56.272

Review 2.  Amyloid diseases of the heart: assessment, diagnosis, and referral.

Authors:  S W Dubrey; P N Hawkins; R H Falk
Journal:  Heart       Date:  2011-01       Impact factor: 5.994

3.  Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement.

Authors:  J Reisinger; S W Dubrey; M Lavalley; M Skinner; R H Falk
Journal:  J Am Coll Cardiol       Date:  1997-10       Impact factor: 24.094

4.  Acute weight gain and diastolic dysfunction as a potent risk complex for post stem cell transplant atrial fibrillation.

Authors:  Kaniz Fatema; Morie A Gertz; Marion E Barnes; Amy D Eisinger; Sue Ann C Ness; Bernard J Gersh; Ivana N M Micallef; James B Seward; Stephen S Cha; Kent R Bailey; Teresa S M Tsang
Journal:  Am J Hematol       Date:  2009-08       Impact factor: 10.047

5.  Melphalan-induced supraventricular tachycardia: incidence and risk factors.

Authors:  Victor Feliz; Saleem Saiyad; Sumana M Ramarao; Hammad Khan; Fabio Leonelli; Maya Guglin
Journal:  Clin Cardiol       Date:  2011-04-27       Impact factor: 2.882

6.  Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma.

Authors:  P Moreau; N Milpied; B Mahé; N Juge-Morineau; M J Rapp; R Bataille; J L Harousseau
Journal:  Bone Marrow Transplant       Date:  1999-05       Impact factor: 5.483

7.  Risk factors and outcome of pulmonary complications after autologous hematopoietic stem cell transplant.

Authors:  Bekele Afessa; Raolat M Abdulai; Walter K Kremers; William J Hogan; Mark R Litzow; Steve G Peters
Journal:  Chest       Date:  2011-07-21       Impact factor: 9.410

8.  Supraventricular tachyarrhythmias after hematopoietic stem cell transplantation: incidence, risk factors and outcomes.

Authors:  J D Hidalgo; R Krone; M W Rich; K Blum; D Adkins; M-Y Fan; R Brown; S Devine; T Graubert; W Blum; M Tomasson; L T Goodnough; R Vij; J DiPersio; H Khoury
Journal:  Bone Marrow Transplant       Date:  2004-10       Impact factor: 5.483

9.  Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative.

Authors:  Morie A Gertz; Stephen M Ansell; David Dingli; Angela Dispenzieri; Francis K Buadi; Michelle A Elliott; Dennis A Gastineau; Suzanne R Hayman; William J Hogan; David J Inwards; Patrick B Johnston; Shaji Kumar; Martha Q Lacy; Nelson Leung; Ivana N M Micallef; Luis F Porrata; Barbara A Schafer; Robert C Wolf; Mark R Litzow
Journal:  Mayo Clin Proc       Date:  2008-10       Impact factor: 7.616

10.  Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation.

Authors:  E Peres; J E Levine; Y A Khaled; R B Ibrahim; T M Braun; O I Krijanovski; S Mineishi; M H Abidi
Journal:  Bone Marrow Transplant       Date:  2009-05-25       Impact factor: 5.483

View more
  13 in total

Review 1.  Arrhythmias and Other Electrophysiology Issues in Cancer Patients Receiving Chemotherapy or Radiation.

Authors:  Federico Viganego; Robin Singh; Michael G Fradley
Journal:  Curr Cardiol Rep       Date:  2016-06       Impact factor: 2.931

2.  The incidence of atrial fibrillation among patients with AL amyloidosis undergoing high-dose melphalan and stem cell transplantation: experience at a single institution.

Authors:  M Arun; D Brauneis; G Doros; A C Shelton; J M Sloan; K Quillen; F L Ruberg; V Sanchorawala; C Varga
Journal:  Bone Marrow Transplant       Date:  2017-07-24       Impact factor: 5.483

Review 3.  Pathophysiology and treatment of cardiac amyloidosis.

Authors:  Morie A Gertz; Angela Dispenzieri; Taimur Sher
Journal:  Nat Rev Cardiol       Date:  2014-10-14       Impact factor: 32.419

4.  The analysis of the parameters of 24-hr ECG Holter monitoring in patients with blood neoplasms undergoing high-dose chemotherapy and stem cell transplantation.

Authors:  Małgorzata Poręba; Paweł Gać; Lidia Usnarska-Zubkiewicz; Witold Pilecki; Kazimierz Kuliczkowski; Grzegorz Mazur; Małgorzata Sobieszczańska; Rafał Poręba
Journal:  Ann Noninvasive Electrocardiol       Date:  2018-01-24       Impact factor: 1.468

Review 5.  Atrial Fibrillation and Cancer Patients: Mechanisms and Management.

Authors:  David L Madnick; Michael G Fradley
Journal:  Curr Cardiol Rep       Date:  2022-08-17       Impact factor: 3.955

Review 6.  Cardiovascular disease and its management in children and adults undergoing hematopoietic stem cell transplantation.

Authors:  Seth J Rotz; Thomas D Ryan; Salim S Hayek
Journal:  J Thromb Thrombolysis       Date:  2020-11-24       Impact factor: 2.300

7.  Arrhythmias in the setting of hematopoietic cell transplants.

Authors:  E S Tonorezos; E E Stillwell; J J Calloway; T Glew; J D Wessler; B J Rebolledo; A Pham; R M Steingart; H Lazarus; R P Gale; A A Jakubowski; W L Schaffer
Journal:  Bone Marrow Transplant       Date:  2015-06-01       Impact factor: 5.483

8.  Cardiovascular Complications of Hematopoietic Stem Cell Transplantation.

Authors:  Anne Blaes; Suma Konety; Peter Hurley
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-04

9.  Autologous Endothelial Progenitor Cells Transplantation for Acute Ischemic Stroke: A 4-Year Follow-Up Study.

Authors:  Jie Fang; Yang Guo; Sheng Tan; Zhanhui Li; Huifang Xie; Pingyan Chen; Kai Wang; Zhicong He; Peng He; Yiquan Ke; Xiaodan Jiang; Zhenzhou Chen
Journal:  Stem Cells Transl Med       Date:  2018-08-29       Impact factor: 6.940

Review 10.  Management of cardiovascular risk in patients with multiple myeloma.

Authors:  Chris Plummer; Christoph Driessen; Zsolt Szabo; María-Victoria Mateos
Journal:  Blood Cancer J       Date:  2019-02-26       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.